Results of CheckMate 67T, a phase 3 noninferiority study comparing subcutaneous and intravenous nivolumab formulations in RCC, were presented at JADPRO 2025.

A phase 2 RCT evaluated progression of prostate-specific antigen and urinary symptoms in men with low-risk prostate cancer who were administered phytochemical-rich food and Lactobacillus probiotic ...

Findings seen for lipoprotein a, remnant cholesterol, and high-sensitivity C-reactive protein.

Cigarette smoking decreased from 42 percent in 1965 to 11.5 percent in 2023; few eligible adults are up to date with lung cancer screening.

Past-month alcohol consumption and believing cancer is not preventable linked to belief that alcohol has no impact on cancer risk.

No significant increase in hazard ratios seen for GI events for semaglutide versus dulaglutide, tirzepatide versus dulaglutide, tirzepatide versus semaglutide.

Rilparencel, a percutaneous minimally invasive injectable product prepared from patients’ own kidney cells, is being developed to treat those with stage 3b or 4 CKD and either type 1 or type 2 ...

Povetacicept is an investigational dual BAFF and APRIL inhibitor being tested for various glomerulonephritis types in clinical trials.

The deal involves Eli Lilly, which makes Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy. The drugs, known as GLP-1 medications, now cost as much as $1,350 a month. Under the ...

Renal diets for chronic kidney disease (CKD) require a dietitian’s assessment, personalization, and support for behavior change.

Study also revealed no increased risk for major adverse cardiovascular events for patients on a GLP-1 RA versus those not on a GLP-1 RA.

Topline data were announced from a phase 3 study evaluating obinutuzumab in patients between 2 and 25 years of age with idiopathic nephrotic syndrome.